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Summary
Background—Male circumcision reduces men’s risk of acquiring HIV and some sexually 
transmitted infections from heterosexual exposure, and is essential for HIV prevention in sub-
Saharan Africa. Studies have also investigated associations between male circumcision and risk of 
acquisition of HIV and sexually transmitted infections in women. We aimed to review all evidence 
on associations between male circumcision and women’s health outcomes to benefit women’s 
health programmes.
Methods—In this systematic review we searched for peer-reviewed and grey literature 
publications reporting associations between male circumcision and women’s health outcomes up 
to April 11, 2016. All biomedical (not psychological or social) outcomes in all study types were 
included. Searches were not restricted by year of publication, or to sub-Saharan Africa. 
Publications without primary data and not in English were excluded. We extracted data and 
assessed evidence on each outcome as high, medium, or low consistency on the basis of agreement 
between publications; outcomes found in fewer than three publications were indeterminate 
consistency.
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Findings—60 publications were included in our assessment. High-consistency evidence was 
found for five outcomes, with male circumcision protecting against cervical cancer, cervical 
dysplasia, herpes simplex virus type 2, chlamydia, and syphilis. Medium-consistency evidence 
was found for male circumcision protecting against human papillomavirus and low-risk human 
papillomavirus. Although the evidence shows a protective association with HIV, it was categorised 
as low consistency, because one trial showed an increased risk to female partners of HIV-infected 
men resuming sex early after male circumcision. Seven outcomes including HIV had low-
consistency evidence and six were indeterminate.
Interpretation—Scale-up of male circumcision in sub-Saharan Africa has public health 
implications for several outcomes in women. Evidence that female partners are at decreased risk of 
several diseases is highly consistent. Synergies between male circumcision and women’s health 
programmes should be explored.
Funding—US Centers for Disease Control and Prevention and Jhpiego
Introduction
Male circumcision has been shown to reduce the risk of HIV acquisition in men due to 
heterosexual exposure in three randomised controlled trials (RCTs).1–3 Shortly after the 
RCTs, WHO and UNAIDS recommended that voluntary medical male circumcision should 
be implemented as an intervention for HIV prevention.4 Voluntary medical male 
circumcision is now an essential component of the HIV prevention strategy in sub-Saharan 
Africa, with almost 15 million circumcisions done between 2007 and 2016.5 To maximise 
the effect of voluntary medical male circumcision on HIV incidence, UNAIDS has set a 
target to circumcise 90% of men aged 15–29 years in priority countries in eastern and 
southern Africa by 2021, totalling 27 million additional voluntary medical male 
circumcisions.6 Circumcision also provides men with other clinical benefits, including 
reduced incidence of herpes simplex virus type 2 (HSV-2) infection and prevalence of 
human papillomavirus (HPV) infection7 (including high-risk HPV subtypes),8,9 penile 
cancer,10 and genital ulcer disease.3 Meta-analyses have been done on these outcomes in 
men.11,12
WHO and UNAIDS noted in their recommendation that voluntary medical male 
circumcision programmes should promote improved health for women;4 evidence exists that 
male circumcision is associated with protection from some diseases in women. Protection 
could either be direct (ie, decreased infectiousness of men with HIV or sexually transmitted 
infections) or indirect (ie, decreased susceptibility of men to infection and therefore 
women’s exposure to infected partners). A 2009 meta-analysis by Weiss and colleagues13 
found lower HIV prevalence in women in countries with high prevalences of circumcision 
than in countries with low prevalences. Moreover, secondary analyses of the circumcision 
RCTs supported the data from observational studies, showing that male circumcision 
protected female partners from other sexually transmitted infections, including bacterial 
vaginosis, trichomonas,14 and HPV.9
We aimed to consolidate existing data on the association of male circumcision with, and its 
effect on, biomedical health outcomes in women, and to clarify the implications of male 
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circumcision on women’s health. Our findings are of greatest relevant to sub-Saharan Africa 
because of the regional scale-up of voluntary medical male circumcision, but are intended to 
be applicable globally.
Methods
Search strategy and selection criteria
For this systematic review we searched published and grey literature for publications 
reporting associations between male circumcision and biomedical (as opposed to 
psychological or social) health, or sexual satisfaction or function outcomes in women, as 
well as women’s knowledge of selected biomedical facts about circumcision. Because 
observational and interventional studies were included, “association” refers to findings from 
both study types, whereas “effect” refers to findings from interventional studies only. The 
search strategy was developed for use in MEDLINE (panel), and thereafter modified based 
on the syntax and capabilities of subsequent databases. Searches were not restricted by study 
design or year, or to sub-Saharan Africa because: some relevant outcomes might not have 
been studied in sub-Saharan Africa; the biological mechanisms underlying the associations 
of male circumcision with sexually transmitted infections are universal; and the potential 
relevance of findings to women’s health programmes is global despite its greatest relevance 
in sub-Saharan Africa, resulting from the regional scale-up of voluntary medical male 
circumcision. Any biomedical outcomes were included and results on women’s knowledge 
about voluntary medical male circumcision and sexual satisfaction and function will be 
reported separately.
Databases of peer-reviewed literature included MEDLINE, EMBASE, Global Health, 
PsychInfo, CINAHL, Cochrane Library, Sociological Abstracts (Proquest), Scopus, and the 
African Index Medicus. Grey literature sources included OPENGREY, Greylit.org, National 
Technical Information Service, PsyExtra, and conference abstracts from international HIV 
conferences: the Conference on Retroviruses and Opportunistic Infections; International 
AIDS Society; and International Society for Sexually Transmitted Disease Research. These 
searches were last updated on April 11, 2016. Full reports of the National Demographic and 
Health Survey and AIDS Indicator Survey from 2008 onward, which contain questions 
about male circumcision, and the AIDSTAR15 resource website were browsed. In 2015, 
bibliographies of key review publications of others obtained through expert 
recommendations were also searched (figure 1). We use “publication” to refer to individual 
sources of data including journal publications, abstracts, white papers, and other sources, 
and “study” to refer to data collection protocols, which sometimes resulted in multiple 
publications.
Data analysis
Titles and abstracts of identified publications were screened by trained reviewers (TSB, IJ, 
SZ, JMdC, LY, AK, and PL). Publications were excluded if they: were duplicates; were not 
in English; did not report primary data; did not describe a sampling method; did not 
distinguish between women who are exposed (ie, with circumcised partners) and unexposed 
(with un-circumcised partners); or did not report a biomedical health outcome.
Grund et al. Page 3
Lancet Glob Health. Author manuscript; available in PMC 2017 December 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Publications not excluded by title or abstract screening were passed to full-text screening by 
trained reviewers (including TSB, IJ, SZ, JMdC, LY, AK, and PL), using the same criteria. 
Additionally, publications were excluded if they reported an overlapping dataset with a more 
recent publication or had obvious errors (different results in the abstract and text). Included 
publications were abstracted by two abstracters into a purpose-built Microsoft Access 
database (SD; MS Access 2013). When available, e-posters served as data sources. 
Abstracted data included publication year, study design, inclusion or exclusion criteria, 
diagnostic methods, sample sizes, and point estimates and uncertainty of associations 
(appendix 1). Incidence was abstracted preferentially over prevalence, intention-to-treat over 
other analytical methods, more-adjusted over less-adjusted outcome estimates, and long 
follow-up periods or late observations in a cohort over short periods or early observations. 
All quantitative outcome measures were included, such as ratios of incidence rate, 
prevalence, odds, hazard, and non-ratio and other measures. Outcomes without clinical 
relevance were not abstracted (eg, individual HPV genotypes). Disagreements were resolved 
by discussion and, if necessary, through review by the first and senior authors. Results of 
studies with only qualitative data were planned to be reported for outcomes with no 
quantitative data (appendix 2).
Estimates of association are presented as comparisons between exposed and unexposed 
women. Point estimates and CIs in appendix 1 have been inverted when reported in the 
opposite manner, and CIs not provided were calculated when possible.
After abstraction, datapoints (referring to a single point estimate of association from a 
specific publication, subgroup, and outcome) were checked for overlap not previously 
identified on the publication level. When different datapoints reported the same outcome, 
measure, subgroup, and data collection period in participant groups in the same location 
with overlapping inclusion criteria, all but one was excluded (excluded points in appendix 
1). Priority was given to datapoints that were peer-reviewed, included a superset of 
participants (rather than a subset), and were more recently published than other datapoints.
Publications listed in appendix 1 were further filtered for display in figure 2. If multiple 
publications provided different measures of the same outcome in the same study sample 
(n=4), only the publication with the preferred measure type was displayed (eg, incidence 
favoured over prevalence). These and non-plottable publications (eg, not providing direction 
of association) make up the non-plottable publications referenced in the table.16–70 Plottable 
publications constitute the group of independent, interpretable data sources. Only the main 
result for each outcome was displayed to avoid exaggeration of the number of publications 
reporting on multiple subgroups. For HIV, four publications reported on subgroups only; the 
datapoint judged most representative of the target population was selected. Point estimates in 
figure 2 are highlighted in appendix 1. Point estimates were plotted on a logarithmic scale. 
Unique symbols (n=4) represent plottable publications with a clear direction of association, 
which were reported in a form that did not allow point estimate calculation. Their locations 
reflect only their direction of association.
Quality grading for RCTs used the Grading of Recommendations, Assessment, 
Development, and Evaluations (GRADE) criteria,71 which rank RCTs as providing evidence 
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of high, moderate, low, or very low quality. Quality grading for observational publications 
used the Newcastle-Ottawa case-control and cohort publication scoring systems, and a 
Newcastle-Ottawa-derived cross-sectional scale developed elsewhere.72 Newcastle-Ottawa 
systems score quality in three categories: sample selection, comparability between groups, 
and outcome or exposure assessment;73 these categories are combined into a single 
summary score.
Quality of the overall body of evidence on each outcome was then assessed, with a modified 
Child Health Epidemiology Research Group74 criteria format (table), which included quality 
of each individual publication’s data on that outcome, magnitude and consistency of 
associations found across plottable publications, and generalisability of results to the 
population for which the findings are most relevant (the general female population in sub-
Saharan African countries with generalised HIV epidemics). Generalisability was high for 
outcomes including only studies in these populations, moderate for outcomes including 
mixed populations, and low for outcomes including only other populations. Consistency of 
evidence on each outcome was established via a prespecified algorithm incorporating study 
design and number, and statistical significance (appendix 2). A meta-analysis was not 
planned.
Role of the funding source
The funders of this study had roles in study design, data collection, data analysis, data 
interpretation, and report writing. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication.
Results
The flowchart of included publications is shown in figure 1. 112 publications met all 
inclusion criteria; datapoints from those not included because of population overlap with 
other publications are listed in appendix 1. Of the remainder, 60 publications had biomedical 
outcomes, which are summarised in this paper. No outcomes had qualitative data without 
quantitative data, so qualitative publications were not reviewed (appendix 2).
Populations included groups in Africa, North America, South America, Asia, and Europe, 
and ages of individuals included ranged from 15 or 18 to 49 or 65 years (appendix 1). Most 
outcomes included at least some data from African general populations, conferring 
moderate-to-high generalisability; however, cervical cancer did not. Except in the case of 
bacterial vaginosis, outcomes had mid-range median-quality scores for observational studies 
and unclear quality grades for RCTs because they did not meet some of the stringent 
GRADE criteria (appendix 1). In the remainder of this section, publications not noted to be 
RCTs were observational, and numbers of datapoints refer to plottable datapoints.
High-consistency evidence was found for five outcomes, which all had protective 
associations with male circumcision: cervical cancer, cervical dysplasia, HSV-2 infection, 
chlamydia, and syphilis (figure 2, table). For cervical cancer, nine datapoints were included 
(none of which were from Africa), conferring low generalisability. All four significant and 
four of five non-significant datapoints showed a protective association. For cervical 
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dysplasia, five datapoints were included from African and other settings, which conferred 
moderate generalisability. The two significant and two of three non-significant datapoints 
showed protective associations. For HSV-2 infection, six data points, one of which was from 
an RCT, were included from African and other settings, which conferred moderate 
generalisability. All datapoints (four significant, two non-significant) showed a protective 
association. For chlamydia, five datapoints were included, which examined participants from 
African and other settings, conferring moderate generalisability. Both significant and two of 
the three non-significant datapoints showed a protective association. For syphilis, six data 
points were included, which examined participants from African and other settings and 
conferred moderate generalisability. All datapoints showed a protective association, two of 
which were significant.
Medium-consistency evidence was found for two outcomes, which reported protective 
associations with HPV infection and low-risk HPV infection. For HPV infection, five 
datapoints, three of which were RCTs, were included and examined participants from 
multiple African and European settings, conferring moderate generalisability. Both 
significant datapoints (two of three RCTs) and two of three non-significant datapoints 
showed a protective association; the remaining datapoint, an RCT, showed a non-significant 
harmful association. For low-risk HPV infection, three studies, two of which were RCTs, 
were included and examined participants from African and European settings conferring 
moderate generalisability. The significant point, an RCT, showed a protective association, 
the other RCT showed a non-significant protective association, and the remaining point 
showed a non-significant harmful association.
Low-consistency evidence was found for seven outcomes because of discrepant values: 
bacterial vaginosis, gonorrhoea, HIV infection, high-risk HPV infection, non-specific genital 
ulcers, trichomonas, and vaginal discharge. The six remaining outcomes, with fewer than 
three studies, were classified as indeterminate consistency: any sexually transmitted 
infection, candidiasis, dysuria, genital warts, high-risk HPV viral load, and Mycoplasma 
genitalium.
Discussion
The scale-up of voluntary medical male circumcision in sub-Saharan Africa has been 
historic, with nearly 15 million circumcisions done between 2007 and 2016.5 We aimed to 
establish which diseases in women had protective associations with male circumcision and 
to clarify whether scale-up of voluntary medical male circumcision could be relevant to a 
wide array of women’s health programmes. Our findings show the substantial evidence for 
the association of male circumcision with decreased risk of several diseases in women.
High-consistency outcomes showed protection associated with circumcision against cervical 
cancer and dysplasia, chlamydia, HSV-2, and syphilis. Few publications reporting cervical 
cancer or dysplasia outcomes took place in Africa; however, biological mechanisms 
underlying protection should be universal. Medium-consistency and low-consistency 
outcomes are discussed further.
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For HPV, publications were from African and European settings. Two of the three RCTs 
from Rakai, Uganda, reported a protective effect of circumcision, which was significant 
among long-term partners of HIV-negative males.9,63 A third RCT64 found a non-significant 
harmful effect (prevalence ratio 1·06, 95% CI 0·92–1·21) and was unique in that enrolled 
male partners were HIV positive. Among the other two publications, both found non-
significant protective associations: one study65 in Spain among women attending routine 
cervical cancer screenings with two or more lifetime sexual partners, and the other study17 
in Nigeria among women attending a gynaecological clinic. Publication qualities were 
mixed—the RCTs and Spanish cross-sectional study65 were scored highest. We conclude 
that the evidence again supports a protective association when male partners are not HIV-
infected.
For low-risk HPV, included datapoints were from a subset of the same publications from 
Uganda and Spain. Of the two RCTs9,64 in Rakai that reported low-risk HPV data, one 
reported a non-significant, minimal-protective effect among partners of HIV-positive men,64 
and the other reported a significant protective effect among partners of HIV-negative men 
(95% CI 0·66–0·90).9 The Spanish cross-sectional study reported a non-significant, harmful 
association between partner circumcision and infection. However, the same study reported 
non-significant protective associations with all-type HPV and high-risk HPV; the association 
with low-risk HPV might represent chance. Publication qualities were generally high. We 
conclude that the evidence supports a protective association when male partners are not HIV 
infected.
For HIV infection—a low-consistency outcome—estimates of association are heavily 
skewed towards protection. Characteristics of publications not reporting protective 
associations are informative. The main RCT of circumcision in HIV-positive men showed a 
non-significant increased risk of HIV acquisition among female partners at 24 months, 
driven by a significant increased risk among those who resumed sex before their wounds 
healed. This finding has become a crucial component of pre-circumcision counselling for 
HIV-positive men.19 A cross-sectional study45 of pregnant Rwandan women showed a 
significant harmful association; confounders are not readily apparent, other than the low 
prevalence of circumcision among male partners (6%), raising the possibility noted by the 
authors that some were circumcised as treatment for sexually transmitted infections. No 
obvious confounders exist for the secondary analyses of data from the VOICE35 and 
Hormonal Contraception and the Risk of HIV Acquisition trials.36 The remaining 16 trials 
included publications that showed significant or non-significant protective associations. 
Excluding the RCT of HIV-positive men, the evidence for protection qualifies as highly 
consistent. Publications showing both harmful and protective associations had a wide range 
of qualities.
Bacterial vaginosis, gonorrhoea, high-risk HPV, trichomonas, non-specific genital ulcers, 
and vaginal discharge were the other low-consistency outcomes. Two patterns underlie this 
heterogeneity. For gonorrhoea and non-specific genital ulcers, the one data point showing a 
harmful association was from the same study,20 which had a participant pool of members of 
high-risk populations (recruited from sexually transmitted infection clinics). The datapoints 
showing harmful associations with trichomonas are from this study20 and another study18 
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with patients from sexually transmitted infection clinics. For bacterial vaginosis, of the two 
datapoints showing a (non-significant) harmful association, the observational point was one 
of the same two high-risk studies,20 and the RCT19 enrolled female partners of HIV-positive 
men. Without this RCT, evidence on bacterial vaginosis would be high consistency for a 
protective association. For high-risk HPV, the single study64 showing a (non-significant) 
harmful association was also an RCT enrolling partners of HIV-positive men. For vaginal 
discharge, the same was true for the datapoint showing a harmful association (prevalence 
ratio 1·13, no CI),19 whereas the other two points had prevalence ratio estimates of 0·9914 
and 1·01.67 We conclude that the protective effects of male circumcision for women against 
many sexually transmitted infections are not evident when male partners are HIV infected. 
In the case of women at high risk of sexually transmitted infections, the mechanisms that 
underlie protection in the general population would be expected to operate in the same way, 
but important confounders might be involved. Alternatively, since these data are derived 
from the same two studies across all outcomes, their populations might have been unique 
because of chance.
Any sexually transmitted infection, candidiasis, dysuria, genital warts, high-risk HPV viral 
load, and Mycoplasma genitalium were indeterminate consistency outcomes with fewer than 
three publications. Research on male circumcision and these outcomes, as well as pregnancy 
and neonatal outcomes (mediated by associations with transmission of sexually transmitted 
infection) would be beneficial. Although existing evidence would make further 
randomisation of men by circumcision status unethical, large observational studies would be 
valuable. Data on self-reportable outcomes, especially pregnancy outcomes (mediated by 
sexually transmitted infections), could be collected easily by demographic surveillance 
studies done for other primary purposes.
We are aware of two publications presenting new data that otherwise qualified for inclusion 
after the cutoff date for this paper. The first examined community-level HIV incidence in 
Rakai, Uganda, before and during scale-up of voluntary medical male circumcision and 
antiretroviral treatment; increasing community-level coverage of voluntary medical male 
circumcision was associated with a significant reduction in HIV incidence among men and a 
non-significant reduction in women.75 This finding is potentially consistent with models 
projecting that the reduction in HIV incidence in women due to voluntary medical male 
circumcision would be delayed relative to those in men.7,76 The second publication, which 
was a baseline analysis of participants in the Partners in Prevention Study,77 found that 
women with circumcised male partners had a lower prevalence of bacterial vaginosis (risk 
ratio [RR] 0·82, 95% CI 0·72–0·94); including this publication would not have changed the 
low consistency score.
Included publications rarely presented data permitting determination of whether a direct 
effect existed; this requires ascertainment of the male partner’s infection status. Available 
data comes primarily from the Rakai RCT follow-up publications. For HIV, no publication 
provided significant evidence for a direct effect. Apart from the RCT in HIV-positive men, 
all publications showed non-significant protective associations,19,46,47 and an earlier meta-
analysis combined some findings into a significant protective result.78 For HSV, results were 
mixed, with one study supporting39,40 and one contradicting41 a direct effect. For HPV, a 
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follow-up of the Rakai RCT63 found a significant protective effect (adjusted RR 0·42, 95% 
CI 0·23–0·76) on incident positivity in women for an HPV genotype present in their male 
partner at baseline, providing the only significant evidence for a direct effect. However, the 
biological mechanism underlying such an effect is unknown.
Limitations of this paper include, for all outcomes, exclusion of non-English-language 
publications and near-universal reliance on self-reporting by women of partner circumcision 
status. We found no information on chancroid, vaginal cancer (mediated by HPV), or 
pregnancy outcomes; information on some other outcomes was insufficient. Although 
formal generalisability to the general population of sub-Saharan Africa varied, the 
mechanistic biological nature of the protection effect makes it plausible that results are 
widely generalisable. Our decision to include only the main outcome from each publication, 
to avoid inflation of the apparent weight of publications that analysed multiple subgroups, 
sometimes resulted in aggregation of different subgroups with divergent point estimates into 
their single combined estimate. Publications reporting multiple outcomes are more heavily 
represented in the total evidence than those reporting one. Although objective standards 
were used for quality assessments, this process has inherent subjective elements. Last, 
evidence was ranked primarily on the basis of consistency and secondarily on individual 
study quality. This was a more standardisable approach because of the heterogeneity of 
study type and number and quality across outcomes; however, this approach is susceptible to 
publication bias, and for some uses including quantitative estimation of association size by 
use of pooled data, individual study scores might be more useful.
Male circumcision has relevance not only to HIV prevention but to the context of the 
broader health needs of women, particularly in sub-Saharan Africa. Male circumcision 
directly addresses two of the top 20 regional causes of female mortality. HIV/AIDS is the 
single biggest cause and cervical cancer is the most common cancer in African women;79,80 
HIV/AIDS is a crucial underlying cause of death from tuberculosis, which is the twelfth 
biggest direct cause of female mortality. Voluntary medical male circumcision programmes 
align with the goals of other reproductive and maternal health interventions prioritised by 
WHO and other organisations—ie, prevention of sexually transmitted infections and HIV, 
screening and treatment for syphilis,81 cervical cancer screening and treatment, and HPV 
vaccination,82 as well as the UN’s Sustainable Development Goals.83 Additionally, 
prevention of syphilis and other sexually transmitted infections in women could prevent 
associated adverse pregnancy outcomes like stillbirth, low birthweight, preterm birth, and 
congenital infection.84 Such health outcomes should be considered in projections of the 
cost-effectiveness and impact of voluntary medical male circumcision. The operational 
intersection between voluntary medical male circumcision and women’s health has also 
begun to be explored, through demand creation for voluntary medical male circumcision 
directed at female partners and emphasising its benefits to them,85 and PEPFAR’s DREAMS 
initiative,86 which includes voluntary medical male circumcision for male partners among its 
strategies for HIV prevention in adolescent girls and young women. Possibilities for broader 
operational synergies between voluntary medical male circumcision and programmes 
directed at other women’s health outcomes are worth exploring, to take further advantage of 
the potential of voluntary medical male circumcision to benefit both women and men.
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Research in context
Evidence before this study
Three randomised controlled trials established that male circumcision provides men who 
engage in heterosexual sex with partial protection against acquiring HIV and some 
sexually transmitted infections. In 2007, WHO recommended that 14 countries with high 
prevalence of HIV and low prevalence of circumcision should scale-up male circumcision 
as an additional HIV prevention strategy; nearly 15 million men and boys were 
circumcised in HIV prevention programmes up to 2016. Observational studies and 
follow-up research at original clinical trial sites have shown that male circumcision also 
decreases the risk of HIV, some sexually transmitted infections, and other adverse health 
outcomes in female partners of circumcised men. Given the magnitude of the male 
circumcision programme for HIV prevention in sub-Saharan Africa, the potential impact 
on women’s health is substantial. However, estimates of association vary among studies 
and the broad effect across numerous women’s health outcomes have not been 
characterised.
Added value of this study
We found that female partners of circumcised men are less likely to have various adverse 
health outcomes, including multiple sexually transmitted infections. Evidence that male 
circumcision is associated with decreased risk of cervical cancer, cervical dysplasia, 
herpes simplex virus type 2 infection, chlamydia, and syphilis in women was highly 
consistent. Evidence that male circumcision is associated with decreased risk of human 
papillomavirus (HPV) infection and low-risk HPV infection in women was of medium 
consistency. The weight of evidence also supports the protective association between 
male circumcision and HIV in women.
Implications of the available evidence
The scale-up of the male circumcision programme has potential benefits for women’s 
health. Strengthening of programmatic linkages and synergies between male 
circumcision and women’s health programmes, including cervical cancer prevention, 
could be maximised in settings in which prevalence of sexually transmitted infections and 
cervical cancer is high. Policy makers, programme implementers, and researchers could 
explore these linkages further to ensure that the benefits of male circumcision for 
women’s health are fully optimised.
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Panel: MEDLINE search strategy
“Circumcision”, “Male/” OR “vmmc.ti,ab.” OR (“circumcis*” ADJ10 [“male*” OR 
“men” OR “man” OR “boy*”]).ti,ab. OR ([“foreskin*” OR “prepuce*”] ADJ5 [“penis” 
OR “penile” OR “male” OR “man” OR “men” OR “boy*”]).ti,ab. AND “Exp Women’s 
Health/” OR “Women/” OR (“women” OR “woman” OR “female*” OR “partner*” OR 
“wife*” OR “wives” OR “sex worker*” OR “prostitute*” OR “girl*” OR “mother*” OR 
“daughter*”).ti,ab.
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Figure 1. Publication selection flow diagram
*Some publications provided biomedical and knowledge data, or qualitative and quantitative 
data, or all of these. The number of publications in these boxes are not a sum of the total 
publications in the parent box immediately above. †Articles reporting quantitative results, 
with or without qualitative results. ‡Articles reporting only qualitative results.
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Figure 2. Point estimates of association between male circumcision and women’s health 
outcomes*
STI=sexually transmitted infection. HPV=human papillomavirus. HR=high risk. LR=low 
risk. HSV-2=herpes simplex virus type 2. RCT=randomised controlled trial. *Datapoints 
without error bars represent estimates for which confidence intervals were not provided or 
calculable. †Protective association but no point estimate calculable. ‡No cases in 
circumcision group.16 §All women with uncircumcised partners were positive.17 ¶No cases 
in circumcision group.16
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